ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, À¯Çüº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Whole Genome Sequencing Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables, Services), By Type, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1587572
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,194,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,571,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,325,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é Àü ¼¼°è ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 66¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö 22.17%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â À¯Àüü ¸ÅÇÎ ÇÁ·Î±×·¥¿¡ ÀüÀå À¯Àüü ½ÃÄö½ÌÀ» µµÀÔÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí Èñ±Í À¯Àü¼º ÁúȯÀ» Æ÷ÇÔÇÑ À¯Àü¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡°ú ÇÔ²² 2021³â 11¿ù ´ºÀ×±Û·£µå Àú³Î ¿Àºê ¸Þµð½Å(New England Journal of Medicine)¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é¿¡ µû¸£¸é, ÀüÀå À¯Àüü ¿°±â¼­¿­ ºÐ¼®Àº ´Ù¾çÇÑ Èñ±Í ÁúȯÀÇ Á¶±â Áø´ÜÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, Á¤¹Ð ÀÇ·á·ÎÀÇ ÀüȯÀ» º¸°íÇß½À´Ï´Ù.

¶ÇÇÑ, WGS¸¦ Ȱ¿ëÇÑ Áúº´ÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ À§ÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù Àεµ³×½Ã¾Æ Á¤ºÎ¿Í À¯Àüü °úÇÐ ÀÌ´Ï¼ÅÆ¼ºê´Â ¼¼°è ±â±ÝÀ¸·ÎºÎÅÍ 3,000¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ ¹Þ¾Æ COVID-19, °áÇÙ, ¾Ï, À¯Àü¼º Áúȯ, ³ú Áúȯ, ´ë»ç¼º Áúȯ µîÀÇ Áúº´À» Á¶±â¿¡ ¹ß°ßÇϰí Ä¡·áÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ½ÃÇàÇÒ ¼ö ÀÖ´Â ½Ã¼³ ³×Æ®¿öÅ©¸¦ ±¸ÃàÇß½À´Ï´Ù.

ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ Àû¿ë ¹üÀ§´Â ±¤¹üÀ§Çϸç, Á¤ºÎ ±â°üÀº Àΰ£, ½Ä¹°, µ¿¹°, ¹Ì»ý¹°ÀÇ À¯Àüü ¿°±â¼­¿­ ºÐ¼®À» À§ÇØ ÀÌ ±â¼úÀ» äÅÃÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº °¢±¹¿¡¼­ ½ÄÁßµ¶ÀÌ ¹ß»ýÇßÀ» ¶§ ½ÄÁßµ¶ º´¿øÃ¼¸¦ ½Äº°Çϱâ À§ÇØ ÀÌ ±â¼úÀ» äÅÃÇßÀ¸¸ç, FDA´Â 2008³âºÎÅÍ ÀüÀåÀ¯Àüü ¿°±â¼­¿­ºÐ¼®(WGS) ÇÁ·Î±×·¥À» ÅëÇØ ÀÌ ±â¼úÀ» äÅÃÇß½À´Ï´Ù. ÆÞ½º ÇÊµå °Ö Àü±â¿µµ¿(PFGE)º¸´Ù ½ÄÁßµ¶ º´¿ø±ÕÀÇ Àüü ±ÕÁÖ¸¦ ´õ È¿À²ÀûÀ¸·Î ½Äº°ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ Áúº´°ú °¨¿°¼º ÁúȯÀ» Àú·ÅÇϰí Á¤È®Çϰí Àû½Ã¿¡ Áø´ÜÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ÀüÀå À¯Àüü ½ÃÄö½Ì Á¦Ç°ÀÌ Ãâ½ÃµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 12¿ù LifeCell International Pvt. Ltd.´Â HaystackAnalytics¿Í ÇÔ²² °áÇÙ °¨¿°ÀÇ Áø´Ü Á¤º¸¸¦ ½Äº°ÇÏ°í ¾àÁ¦ ³»¼º ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ ÀüÀå À¯Àüü ½ÃÄö½Ì °Ë»ç TB¸¦ Ãâ½ÃÇß½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ÀÌ °Ë»ç¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© SARS-CoV-2ÀÇ ½Å¼ÓÇÑ ½Äº°°ú ÆÒµ¥¹ÍÀ» °ü¸®ÇÒ ¼ö ÀÖ´Â Áø´Ü Å×½ºÆ®ÀÇ °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àü ¼¼°è Á¤ºÎ°¡ ¿¬±¸ ±â°ü ¹× ±â¾÷ ºÎ¹®°ú Çù·ÂÇÏ¿© SARS-CoV-2ÀÇ ½Äº° ¹× Áø´ÜÀ» À§ÇØ ÀÌ ¹æ¹ýÀ» »ç¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¿©·¯ ±â¾÷ÀÌ SARS-CoV-2 ¹ÙÀÌ·¯½º °¨½Ã¸¦ À§ÇÑ À¯Àüü ¼­ºñ½º ¹× ½Å¼ÓÇÑ ¼Ö·ç¼ÇÀ» ¹ßÇ¥Çß½À´Ï´Ù. ¿¹¸¦ µé¾î, QIAGENÀº SARS-CoV-2 °¨½Ã¸¦ À§ÇÑ ÀüÀå À¯Àüü ½ÃÄö½Ì ¼­ºñ½º SARS-CoV-2 °¨½Ã¸¦ Á¦°øÇÏ¿© °­·ÂÇÑ º¯Á¾À» ½Äº°Çϰí, °¡´ÉÇÑ ¹ßº´À» ÃßÀûÇϰí, ¹é½Å ¿¬±¸ ¹× ÀǾàǰ °³¹ßÀÇ ÁøÀüÀ» µµ¸ðÇϰí ÀÖ½À´Ï´Ù.

ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : Á¦Ç°°ú ¼­ºñ½º ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : À¯Çü ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : ¿öÅ©ÇÃ·Î¿ì ºñÁî´Ï½º ºÐ¼®

Á¦7Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦8Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦9Àå ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå : Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦10Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Whole Genome Sequencing Market Growth & Trends:

The global whole genome sequencing market size is projected to reach USD 6.67 billion by 2030, expanding at a CAGR of 22.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to the rising adoption of whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders. According to the study published in the New England Journal of Medicine in November 2021, whole genome sequencing could lead to the early diagnosis of a wide range of rare diseases and a reported transition to precision medicine.

Furthermore, the growing investment in R&D for the early detection and treatment of disorders with the aid of WGS is expected to propel the growth of the market. For instance, in February 2023, the government of Indonesia and the Genome Science Initiative, with the aid of a USD 30 million investment from the Global Fund, established a network of facilities to perform the method for the early detection and treatment of disorders, including COVID-19, tuberculosis, cancer, genetic disorders, brain diseases, and metabolic disorders.

Whole genome sequencing has a wide range of applications, and government bodies are adopting these technologies for sequencing the genomes of humans, plant, animal, and microbes, which is expected to drive market growth. For instance, U.S. Food & Drug Administration (FDA) adopted the method to identify foodborne pathogens during foodborne disease outbreaks across the countries. The FDA has adopted this technology since 2008 under the Whole Genome Sequencing (WGS) program as it enables it to distinguish all strains of foodborne pathogens more efficiently than pulse-field gel electrophoresis (PFGE).

The rising technological advancements have led to the launch of innovative whole genome sequencing products that offer an affordable, accurate, and timely diagnosis of various diseases and infections. This is contributing to the growth of the market. For instance, in December 2022, LifeCell International Pvt. Ltd. collaborated with HaystackAnalytics to launch TB, a whole genome sequencing test to identify the diagnostic information on tuberculosis infections and tackle the drug resistance challenge.

The COVID-19 pandemic led to an increased demand for the method globally, which enabled the rapid identification of SARS-CoV-2 and the development of possible diagnostic tests to manage the outbreak. Hence, governments across the globe collaborated with research organizations and the corporate sector to use the method to identify and diagnose SARS-CoV-2. Several companies have launched genomic services and rapid solutions for the surveillance of the SARS-CoV-2 virus. For instance, QIAGEN offers the whole genome sequencing services SARS-CoV-2 surveillance for the identification of potent mutants, tracing of possible outbreaks, and advancement of vaccine research and drug development.

Whole Genome Sequencing Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Whole Genome Sequencing Market: Product & Service Business Analysis

Chapter 5. Whole Genome Sequencing Market: Type Business Analysis

Chapter 6. Whole Genome Sequencing Market: Workflow Business Analysis

Chapter 7. Whole Genome Sequencing Market: Application Business Analysis

Chapter 8. Whole Genome Sequencing Market: End Use Business Analysis

Chapter 9. Whole Genome Sequencing Market: Regional Business Analysis

Chapter 10. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â